KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Invested Capital (2016 - 2025)

Travere Therapeutics' Invested Capital history spans 15 years, with the latest figure at $114.8 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 10.12% year-over-year to $114.8 million; the TTM value through Dec 2025 reached $114.8 million, down 10.12%, while the annual FY2025 figure was $114.8 million, 10.12% down from the prior year.
  • Invested Capital reached $114.8 million in Q4 2025 per TVTX's latest filing, up from $73.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $362.7 million in Q1 2021 to a low of $15.1 million in Q2 2024.
  • Average Invested Capital over 5 years is $164.8 million, with a median of $125.6 million recorded in 2023.
  • Peak YoY movement for Invested Capital: tumbled 87.72% in 2024, then skyrocketed 570.66% in 2025.
  • A 5-year view of Invested Capital shows it stood at $309.5 million in 2021, then plummeted by 83.89% to $49.9 million in 2022, then soared by 302.82% to $200.8 million in 2023, then crashed by 36.38% to $127.8 million in 2024, then dropped by 10.12% to $114.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Invested Capital are $114.8 million (Q4 2025), $73.6 million (Q3 2025), and $101.6 million (Q2 2025).